Acrux Ltd
Company Profile
Business description
Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone Topical Solution, and among others.
Contact
103-113 Stanley Street
West Melbourne
MelbourneVIC3003
AUST: +61 383790100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
36
Stocks News & Analysis
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
stocks
Going into earnings, Is Meta stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,941.50 | 15.30 | 0.17% |
CAC 40 | 7,763.38 | 34.84 | -0.45% |
DAX 40 | 24,119.80 | 188.00 | -0.77% |
Dow JONES (US) | 44,323.07 | 19.12 | -0.04% |
FTSE 100 | 9,012.39 | 0.60 | -0.01% |
HKSE | 25,130.03 | 135.89 | 0.54% |
NASDAQ | 20,974.18 | 78.52 | 0.38% |
Nikkei 225 | 39,774.92 | 44.19 | -0.11% |
NZX 50 Index | 12,833.74 | 127.77 | -0.99% |
S&P 500 | 6,305.60 | 8.81 | 0.14% |
S&P/ASX 200 | 8,677.20 | 9.00 | 0.10% |
SSE Composite Index | 3,581.86 | 22.07 | 0.62% |